The agreement was signed at the CPHI Milan pharmaceutical industry exhibition in early October this year, and the new medicine is expected to become available to patients soon. The partnership combines Adalvo\u2019s expertise in pharmaceutical product development and supply with Olpha\u2019s sales infrastructure, market knowledge and presence in all three Baltic countries.<\/p>\n\n\n\n
New treatment options are particularly important in Latvia, where more than 100,000 people are registered as living with diabetes. According to the Centre for Disease Prevention and Control, 105,608 people in Latvia were registered as having diabetes at the end of 2025, an increase of 2.1% compared with the previous year. Approximately 7,000 people were newly diagnosed with diabetes during the year.[1]<\/p>\n\n\n\n
Timely diagnosis, appropriate treatment and regular health monitoring can help prevent or delay the development of complications. Broader treatment options, alongside a healthy diet and physical activity, therefore play an essential role in patient care.<\/p>\n\n\n\n
\u201cThis agreement is a significant strategic step in the company\u2019s development as we actively expand both our presence in Europe and our product portfolio. Our partnership with Adalvo strengthens our offering in the strategically important field of diabetes and obesity treatment and lays the foundation for long-term growth in the Baltic countries. By combining our regional expertise and sales infrastructure with Adalvo\u2019s product development capabilities, we aim to improve access to treatment options and deliver long-term benefits for patients and healthcare professionals in Latvia, Lithuania and Estonia,\u201d<\/em> says Dr Juris Hme\u013c\u0146ickis, Chairman of the Management Board of Olpha AS, who holds a doctorate in chemistry.<\/strong><\/p>\n\n\n\n The partnership aligns with both companies\u2019 growth strategies. For Latvian pharmaceutical manufacturer Olpha, it offers an opportunity to expand its product portfolio and strengthen its position in the Baltics while pursuing broader development plans in Europe. For Adalvo, the partnership strengthens its position in the GLP-1 receptor agonist segment and supports the strategic objectives of its dedicated GLP-1 business unit. GLP-1 receptor agonists are prescription medicines that mimic the action of the naturally occurring hormone GLP-1 and help regulate blood glucose levels.<\/p>\n\n\n\n